Yao Wang1,2, Qi Chen3,4, Min Zhao5, Kelly Walton1,6, Craig Harrison1,6, Guiying Nie1,2,7. 1. Hudson Institute of Medical Research, Clayton, Victoria 3168, Australia. 2. Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria 3800, Australia. 3. The Hospital of Obstetrics & Gynaecology, Fudan University, Shanghai 200090, China. 4. Department of Obstetrics & Gynaecology, The University of Auckland, Auckland 1142, New Zealand. 5. Wuxi Maternity and Children's Health Hospital, Nanjing Medical University, Jiangsu 214002, China. 6. Department of Physiology, Monash University, Clayton, Victoria 3800, Australia. 7. Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia.
Abstract
Context: Preeclampsia (PE) can be classified into early-onset (<34 weeks of gestation) and late-onset (>34 weeks of gestation) subtypes. Soluble endoglin, an auxiliary receptor for transforming growth factor (TGF)-β ligands, is increased in PE circulation and believed to inhibit TGF-β action by sequestering the ligands. However, soluble endoglin, with a low affinity to TGF-β ligands, has been demonstrated to have little effect by itself on TGF-β action. Objectives: We examined whether multiple soluble TGF-β receptors are elevated in PE circulation and whether they synergistically block TGF-β signaling. Design: TGF-β receptors were measured using enzyme-linked immunosorbent assay in sera collected from preeclamptic pregnancies and gestation-age-matched controls. TGF-β signaling was assessed using an in vitro bioassay and a tube formation assay. Results: TGF-β type I, II, and III receptors were all identified in pregnant serum; all were substantially elevated in early-onset but not late-onset PE. Endoglin was increased in both subtypes. At the greatest concentrations detected in PE, none of these soluble TGF-β receptors alone, including endoglin, inhibited TGF-β signaling. However, when all four soluble receptors were present, signaling of both TGF-β1 and TGF-β2 was substantially reduced. Removal of any one of these soluble receptors alleviated TGF-β1 inhibition; however, removal of soluble TGFβRIII was necessary to relieve TGF-β2 inhibition. Conclusions: Multiple soluble TGF-β receptors are present in pregnant circulation and elevated in early-onset PE; they synergistically inhibit TGF-β signaling, which might be more likely to occur in early-onset than late-onset PE. Reducing soluble TGFβRIII, rather than endoglin, would be more effective in alleviating the inhibition of both TGF-β1 and TGF-β2 signaling in PE.
Context: Preeclampsia (PE) can be classified into early-onset (<34 weeks of gestation) and late-onset (>34 weeks of gestation) subtypes. Soluble endoglin, an auxiliary receptor for transforming growth factor (TGF)-β ligands, is increased in PE circulation and believed to inhibit TGF-β action by sequestering the ligands. However, soluble endoglin, with a low affinity to TGF-β ligands, has been demonstrated to have little effect by itself on TGF-β action. Objectives: We examined whether multiple soluble TGF-β receptors are elevated in PE circulation and whether they synergistically block TGF-β signaling. Design: TGF-β receptors were measured using enzyme-linked immunosorbent assay in sera collected from preeclamptic pregnancies and gestation-age-matched controls. TGF-β signaling was assessed using an in vitro bioassay and a tube formation assay. Results: TGF-β type I, II, and III receptors were all identified in pregnant serum; all were substantially elevated in early-onset but not late-onset PE. Endoglin was increased in both subtypes. At the greatest concentrations detected in PE, none of these soluble TGF-β receptors alone, including endoglin, inhibited TGF-β signaling. However, when all four soluble receptors were present, signaling of both TGF-β1 and TGF-β2 was substantially reduced. Removal of any one of these soluble receptors alleviated TGF-β1 inhibition; however, removal of soluble TGFβRIII was necessary to relieve TGF-β2 inhibition. Conclusions: Multiple soluble TGF-β receptors are present in pregnant circulation and elevated in early-onset PE; they synergistically inhibit TGF-β signaling, which might be more likely to occur in early-onset than late-onset PE. Reducing soluble TGFβRIII, rather than endoglin, would be more effective in alleviating the inhibition of both TGF-β1 and TGF-β2 signaling in PE.
Authors: Shivalingappa Venkatesha; Mourad Toporsian; Chun Lam; Jun-ichi Hanai; Tadanori Mammoto; Yeon M Kim; Yuval Bdolah; Kee-Hak Lim; Hai-Tao Yuan; Towia A Libermann; Isaac E Stillman; Drucilla Roberts; Patricia A D'Amore; Franklin H Epstein; Frank W Sellke; Roberto Romero; Vikas P Sukhatme; Michelle Letarte; S Ananth Karumanchi Journal: Nat Med Date: 2006-06-04 Impact factor: 53.440
Authors: Anne Cathrine Staff; Samantha J Benton; Peter von Dadelszen; James M Roberts; Robert N Taylor; Robert W Powers; D Stephen Charnock-Jones; Christopher W G Redman Journal: Hypertension Date: 2013-03-04 Impact factor: 10.190
Authors: Maree Bilandzic; Yao Wang; Nuzhat Ahmed; Rodney B Luwor; Hong Jian Zhu; Jock K Findlay; Kaye L Stenvers Journal: Cancer Lett Date: 2014-08-13 Impact factor: 8.679
Authors: Paul G Farnworth; Yao Wang; Ruth Escalona; Pauline Leembruggen; Guck T Ooi; Jock K Findlay Journal: Endocrinology Date: 2007-07-26 Impact factor: 4.736
Authors: Ivana Nemeckova; Agnieszka Serwadczak; Barbara Oujo; Katerina Jezkova; Jana Rathouska; Petra Fikrova; Michala Varejckova; Carmelo Bernabeu; Jose M Lopez-Novoa; Stefan Chlopicki; Petr Nachtigal Journal: PLoS One Date: 2015-03-13 Impact factor: 3.240
Authors: Natalia I Agalakova; Vitaly A Reznik; Olga V Nadei; Ivan A Ershov; Olga S Rassokha; Marina L Vasyutina; Dmitry O Ivanov; C David Adair; Michael M Galagudza; Alexei Y Bagrov Journal: Am J Hypertens Date: 2020-05-21 Impact factor: 2.689
Authors: Eunate Gallardo-Vara; Simon Tual-Chalot; Luisa M Botella; Helen M Arthur; Carmelo Bernabeu Journal: Dis Model Mech Date: 2018-09-21 Impact factor: 5.758